Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 8,146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: ondansetron, moxifloxacin, saline; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteogenesis Imperfecta (OI)
Interventions: AGA2115, Placebo; Drug · Other
Lead sponsor: Angitia Incorporated Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more

Conditions: Child Abuse
Interventions: Child Abuse Prevention Problem Solving, Active Control Group; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Mexican or American foods; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteers
Interventions: AZD4831; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Dyslipidemia
Interventions: AZD0780, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Skin Health, Dermatology, Skin Care
Interventions: Hand Serum and Glove; Other
Lead sponsor: Habelo Beauty; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Heart Failure
Interventions: Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,614,719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Sports Injury, Intermittent Fasting
Interventions: Soccer Heading, Intermittent Fasting; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Constipation, Bloating
Interventions: PRIM-DJ2727, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Suicidal Ideation
Interventions: Treatment; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 18 Years and older
Enrollment: 864 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions: Lumason, Sonazoid; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer Disease
Interventions: Bryostatin 1, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Colton, California • San Diego, California • Atlantis, Florida + 16 more

Conditions: Healthy
Interventions: SSP-004184SS; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ulcerative Colitis
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 15
States / cities: Camarillo, California • Los Angeles, California • Mission Hills, California + 12 more

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 65 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Volunteers
Interventions: Ziresovir 125 mg, Ziresovir 500 mg, Placebo, Moxifloxacin hydrochloride tablet 400 mg; Drug
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Interventions: Rozanolixizumab, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more

Conditions: Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
Interventions: History and physical exam., Blood draw., Pulmonary function testing., Albuterol inhaler.; Procedure · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2033
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: No Condition
Interventions: Connection to community services through case management, TOGETHER Workshop, Employment Support Services; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: College Park, Maryland • Gaithersburg, Maryland • Falls Church, Virginia

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more

Conditions: Suicide Risk
Interventions: TIPS Program, TIPS Program + ED-SAFE; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 32,406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hepatic Encephalopathy, Covert Hepatic Encephalopathy, Cirrhosis, Sleep Disturbances and Insomnia
Interventions: Melatonin tablet 3 mg once daily, Thiamine; Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Substance Abuse
Interventions: Yappalli; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: McAlester, Oklahoma

Search by objective public record fields.

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

A Medical Home-Based Intervention to Prevent Child Neglect in High-Risk Families

COMIDAS Comparing Original Mexican Diets and Standard US Diets

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

A Trial to Examine the Efficacy of a Hand Serum and Glove Combination.

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

The Effect of Intermittent Fasting on Acute Subconcussive Head Impacts

A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

Digital Narrative Bibliotherapy as a Scalable Intervention for Suicidal Thoughts

Y-90 Treatment Response Using Transarterial Radioembolization

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

TOGETHER: A Couple's Model to Enhance Relationships and Economic Stability

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Telehealth to Improve Prevention of Suicide (TIPS)

Affect of Melatonin on Sleep and Cognition in Cirrhosis

Yappalli - The Road to Choctaw Health